To determine how adults in the United States view non-invasive prenatal testing using cell-free fetal DNA (cffDNA testing) in order to help estimate uptake. STUDY DESIGN: A national sample of 1861 US-based adults was surveyed using a validated online survey instrument. The survey was administered by a commercial survey research company. Respondents were randomized to receive a survey about prenatal testing for trisomy 13 and 18 or trisomy 21. Participants were asked to select among testing modalities, including cffDNA testing, and rank the features of testing that they considered most important to decision making. RESULT: There was substantive interest in the use of cffDNA testing rather than traditional screening mechanisms, with a minority of respondents reporting that they would support the use of both methods in combination. The lower rates of false-negative and false-positive test results and the ability to use the test earlier in the pregnancy were the most highly rated benefits of cffDNA testing. Participants expressed strong support for diagnostic confirmation via invasive testing after a positive result from either screening or cffDNA testing. However, almost one-third of participants reported that they would not endorse the use of either invasive or non-invasive prenatal testing.
INTRODUCTION
The emergence of non-invasive forms of prenatal genetic testing has the potential to expand the availability of highly sensitive and specific prenatal testing. In particular, new tests that target and analyze cell-free fetal DNA (cffDNA) in the maternal bloodstream as early as 9 weeks into pregnancy 1 have generated considerable public interest. 2 The growing interest in these technologies stems from cffDNA testing's distinguishing features: the absence of procedure-related risks of miscarriage and the potential to obtain results earlier in gestation compared with the currently available prenatal diagnostic tests. 3, 4 Over the past decade, several biotechnology companies-including Sequenom, Verinata Health, Natera and Ariosa Diagnostics-and academic laboratories have validated cffDNA techniques for the detection of fetal RhD blood type, sex, and, most recently, trisomy 13, 18 and 21 (Down syndrome), monosomy X and other sex chromosome aneuploidies. 1, 5, 6 Tests using these techniques are now entering an expanding $1.3 billion prenatal testing market in the United States. 7, 8 The industry expects non-invasive prenatal testing methods using cffDNA (cffDNA testing) to supplement, and potentially replace, existing first-trimester combined screening and significantly reduce the number of invasive procedures performed 9 because cffDNA testing offers increased sensitivity and specificity (between 98.0 and 99.0% sensitivity and 99.5 and 99.8% specificity) over existing screening measures together with early usage and without the procedure-related miscarriage associated with diagnostic testing. 1 Professional societies have begun to release preliminary guidelines supporting the use of cffDNA testing as second-tier screening in high-risk pregnancies. 10, 11 This study explores the interest of individuals of reproductive age in cffDNA testing in relation to other prenatal testing mechanisms. Past studies on American attitudes towards prenatal testing were largely conducted before non-invasive testing methods became clinically available. 12 One of the few studies addressing non-invasive testing, by Tischler et al., 13 found that 71.9% of a small sample of pregnant women were interested in cffDNA testing as a replacement for amniocentesis because of the decreased risk to the fetus. Zamerowski et al.
14 similarly found that women undergoing invasive diagnostic testing in four US metropolitan clinics responded positively to the potential of non-invasive prenatal testing using whole fetal cells. In the United Kingdom, Lewis et al.
cffDNA testing, 16 studies conducted on the views of non-invasive testing among end users in the United States have been limited to small, specific populations of pregnant women. 13 There has yet to be a comprehensive national study on the target users of this technology-individuals of reproductive age-and their view on cffDNA testing as a possible supplement to or replacement for other methods of testing, including invasive measures such as amniocentesis.
METHODS

Survey design
We designed a 25-question online survey for distribution to a representative selection of the general public in the United States regarding their choices among cffDNA testing, conventional screening and diagnostic procedures such as amniocentesis. Here, we present data on the responses of individuals of reproductive age, as defined by age self-reported between 18 and 44 years. Participants were randomized between one of two versions of the survey-focusing on testing for either trisomy 13 and 18 or trisomy 21-in order to asses whether the severity of the condition being tested affected uptake rates. Participants were randomized in order to avoid any cognitive bias associated with the order in which conditions were presented. 17 We were interested in testing whether allowing individuals to consider higher morbidity vs lower morbidity conditions independently would impact testing decisions.
At the beginning of the survey, short descriptions of either trisomy 13 and 18 or trisomy 21 were provided to the viewer (see Supplementary Appendix A) in conjunction with a table highlighting the features of different testing options and their costs. The tests presented were designed to mirror the current abilities of first-trimester combined screening and cffDNA testing. cffDNA testing was described as more expensive than screening in accordance with the current state of the US prenatal testing market. 7 Participants were asked to state a preference as to which test should be used in the event of a pregnancy in themselves or in someone they are close to. Survey questions were derived from previous empirical data on prenatal testing as well as pertinent concepts in the prenatal medicine literature. 18, 19 A broader team of bioethics scholars reviewed the survey's text for readability and content. The survey consisted of 10 questions on the topic of prenatal testing choices, some of which used a 5-point Likert scale to determine the importance the participant assigned to the features of different tests. Participants were then asked to consider invasive follow-up and whether they would consider termination of an affected pregnancy. Fifteen demographic questions were included.
Data collection and analysis
The research team contracted a web-based survey provider to electronically distribute both versions of the study to individuals aged 18-44 years throughout the United States. The online survey company provides a quality-assured sample of survey respondents by validating prospective panelists to ensure that they are providing accurate data and deduplicating survey responses by using digital fingerprinting.
Participants were compensated for their time spent in completing the survey via the commercial provider. Responses were downloaded to a spreadsheet via a secure webpage by the research team, and statistical analysis was performed using the SPSS Statistics Standard program version 20.0 in consultation with the Stanford University biostatistics consultation service. This study was approved by the Stanford University Institutional Review Board.
RESULTS
A pilot version of the study was sent to~200 users (100 individuals for each version of the survey) to ensure that participants could understand and complete the survey. Minor revisions were made to enhance the clarity of the questions, and the final survey was sent to members of the company's panel, representative of the primary demographic features of the US general public. Including the pilot sample, 1861 individuals of reproductive age completed the survey. Because the commercial survey provider measures participation in terms of completed surveys rather than invitations sent, the total response rate is unknown.
Population characteristics Both income and education were evenly distributed and most (90%+) participants had a high-school degree or higher education. Age and gender in the sample were well distributed, with slightly more women than men responding (52.6% female to 47.3% male for trisomy 13 and 18, and 55.8% female to 44.1% male for trisomy 21). A majority, over 80% of the sample, identified as white; over Table 1 . In order to establish representativeness, we compared demographic measures with the 2010 US Census data (for gender, age, ethnicity, race, educational attainment, household income and health insurance status) using χ Choosing between screening and cffDNA testing As Table 1 (CI = 95%) demonstrates, when asked to choose between testing modalities, respondents reported a substantive projected uptake of cffDNA testing (trisomy 13/18 37.7%, trisomy 21 38.9%) over traditional screening mechanisms (trisomy 13/18 22.1%, trisomy 21 25.2%), with a small minority (trisomy 13/18 8.7%, trisomy 21 6.5%) expressing an interest in using both tests. There was no statistically significant difference between the two cohorts in those who chose cffDNA over screening. However, there was a statistically significant difference between the two cohorts (P = 0.001) in those who wished to undergo both tests, with a higher percentage electing to undergo both tests for trisomy 13 and 18. A significant segment of the respondents (trisomy 13/18 31.4%, trisomy 21 29.2%) declined either form of testing.
Participants were asked to rank the features of testing that they considered most important for decision making (see Figure 1) . The lowered rate of false negatives and false positives and the ability to use the test earlier in the pregnancy were the most highly rated benefits of cffDNA testing. Two other strongly rated factors were the cost of cffDNA testing and the recommendation of a healthcare provider. Finally, the beliefs of family and friends were consistently ranked lowest among the factors provided.
Choosing whether or not to undergo invasive testing Participants were asked whether they would elect for invasive confirmatory testing after receiving a prenatal diagnosis of trisomy 13 or 18 or trisomy 21. The results are included in Figure 1 (CI = 95%). Desire for invasive confirmation was higher after receiving a positive result from both screening and cffDNA testing, with approximately half of the participants electing to receive confirmatory testing after a positive screening result (trisomy 13/18 53.3%, trisomy 21 50.7%) or after a positive cffDNA testing result (trisomy 13/18 46.4%, trisomy 21 46.5%). Uptake rates were lower following a negative testing result from screening (trisomy 13/18 43.8%, trisomy 21 40.8%) and cffDNA testing (trisomy 13/18 33.7%, trisomy 21 32.1%). There were no significant differences between rates for trisomy 13 and 18 and rates for trisomy 21 ( Figure 2) .
The accuracy of invasive testing was the highest-rated factor when respondents were asked which factors were most influential in deciding whether or not to undergo invasive testing. However, this was closely followed by the risk of miscarriage. The discomfort of invasive procedures and the recommendation of a medical provider were also ranked as considerations for both conditions. Timing was also ranked fairly low, and cost was ranked considerably lower as a decision-making factor when considering invasive vs non-invasive testing. Finally, the belief of family and friends was once again ranked lowest in considering testing. Rankings are displayed in Figure 3 .
Finally, participants were asked whether they would consider termination following a diagnosis of trisomy. (When trisomy 13 or 18 is detected in a fetus, most parents choose not to continue the pregnancy. Do you think this is a decision you would consider?) As shown in Figure 4 , a statistically significant (P = 0.001) percentage (trisomy 13/18 49.8%, trisomy 21 41.3%) were more likely to consider termination for trisomy 13/18 than for trisomy 21 . Approximately half (trisomy 13/18 50.1%, trisomy 21 58.6%), however, reported that they would not consider termination after a diagnosis of trisomy 13 and 18 or 21.
DISCUSSION
Reported support for cffDNA testing Overall, these data show support among US adults of reproductive age for the uptake of non-invasive prenatal testing for aneuploidy over current first-trimester combined screening methods. Recent studies have suggested that cffDNA testing is more cost effective as a follow-up to a positive first-trimester screen. 20 However, our results suggest that patients would not necessarily support such an approach, as only 8.7% for trisomy 13/18 or 6.5% for trisomy 21 indicated that they would opt for both screening and cffDNA testing. Furthermore, unlike previous testing estimates that the availability of cffDNA testing would decrease the uptake of invasive testing for 66%, 9 46% of our participant population indicated that they would request confirmatory testing, even after a negative result from cffDNA. This result suggests that, in the hypothetical, participants devalue the risk of invasive procedures in favor of a desire for more conclusive information. Given the decline in uptake of invasive procedures in general, 21 it is probable that this number is significantly higher than the actual clinical uptake of invasive procedures. It does, however, emphasize the importance potential parents place on certainty in prenatal results.
Respondents clearly indicated the value of clinical recommendation in selecting among testing options. However, a pilot study of providers also indicated that many felt unprepared to have a knowledgeable conversation about cffDNA testing, suggesting that broader clinician education about the capabilities and limitations of non-invasive testing will be necessary. 16 Furthermore, genetic counselors have expressed concerns that other medical professionals do not offer adequate pre-test counseling to ensure informed consent for cffDNA testing, 3, [22] [23] [24] whereas physicians have reported a preference for professional genetic counseling services to be administered after a positive test result, indicating a discomfort with physicians attempting to offer effective genetic counseling. Plans to expand the offer of cffDNA testing into wider clinical use for average-risk pregnancies will exacerbate the lack of adequate counseling services available to women considering prenatal testing options. On a broader level, the input of pertinent regulatory agencies may become increasingly important as non-invasive prenatal testing expands. Given that the accuracy of testing is the most highly valued feature in prenatal testing, additional measures will be necessary to ensure that novel tests are rigorously validated and monitored.
Approximately a third of participants indicated that they would continue to decline all testing, including cffDNA testing, despite the potential to receive more accurate results non-invasively. These results are supported by Tischler et al. 13 and are consistent with the limited clinical reports from academic medical centers. 25 However, other studies involving individuals who decline invasive prenatal testing have emphasized that risk to the fetus is a significant motivation for declining testing. 26 One explanation for this may be that the risk to the fetus may serve as a form of proxy anxiety for cultural and religious beliefs surrounding the permissibility of termination; because patients may be uncomfortable considering elective termination as a valid option, risk is used as an alternative explanation for why testing is unacceptable. Previous studies have supported the idea that personal and ethical beliefs can significantly mediate patient choices regarding prenatal testing. 27 Despite the modest importance assigned to personal beliefs in the current sample, it is probable that those who do express strong cultural or religious values contribute significantly to the proportion of individuals in the sample who said they would decline testing.
The number of individuals who continue to express a desire to avoid all prenatal testing is potentially worrisome because of the potential for cffDNA testing to compress the informed consent process leading up to near-diagnostic results. cffDNA testing can be carried out at a time in the pregnancy when women generally undergo blood draws for a variety of reasons, and observers have frequently expressed concern that pregnant women will have difficulty in distinguishing aneuploidy testing from other routine maternal tests. [28] [29] [30] Indeed, recent data show that even women who remember formulating a plan, with regard to whether or not to receive quad screen testing, end up inadvertently acting against their intentions due to a lack of awareness of what kind of testing to which they are agreeing. 31 Furthermore, due to the lack of physical risk in cffDNA testing, there is concern that medical professionals may be inclined to view non-invasive testing as information with 'no downside', 32, 33 an attitude that may erode the informed consent process. 34 For instance, van den Heuvel et al. 35 found that service providers recommended less stringent informed consent procedures when hypothetically referring for non-invasive vs invasive testing. We echo the concerns of other observers who note that it is important to maintain the integrity of the informed consent process even when testing is conducted early and non-invasively.
35-38
Finally, it is clear that cost remains a factor in prenatal decision making, highlighting the significant challenges of integrating cffDNA testing into the US health-care system. Although a few states have subsidized prenatal screening programs using firsttrimester combined screening, it is unclear how quickly, if at all, cffDNA testing will be taken up by public payors, including both Medicaid and state screening programs. For third-party payors who might otherwise cover these costs, cffDNA testing will have to prove that it significantly improves detection rates of targeted conditions or substantively reduces the number of invasive procedures before it will be widely reimbursable. Reimbursement for non-invasive tests using cffDNA among private insurers has thus far been inconsistent among US providers; 3, 22 to date, California is the only state that includes NIPT in its universally available prenatal screening regime. 39 Furthermore, if patients are unwilling to rely on cffDNA testing in making decisions about a pregnancy and decide to undergo amniocentesis regardless of their results, then the timing advantages of cffDNA testing may be reduced. 3 Differences between trisomy 13/18 and 21 The reported uptake of testing of any kind did not significantly differ across trisomies, despite the fact that trisomies 13/18 were presented as most often fatal, whereas trisomy 21 was presented . Expressed willingness to consider termination after an invasive diagnosis. Statistically significant difference between conditions. P o0.001, CI = 95%.
Attitudes towards non-invasive prenatal testing M Allyse et al as a condition with which affected individuals may lead long, relatively healthy lives (see Supplementary Appendix A). The only significant difference came in the small proportion of people who indicated that they would choose to undergo both screening and cffDNA testing, suggesting that the additional reassurance was considered important when considering a fatal condition. On the one hand, as we report elsewhere, the inherent value of information is frequently cited as a motivation for undergoing testing, even when participants report that they intend to carry the pregnancy to term regardless of testing results. This finding may suggest that respondents who said they would choose testing value prenatal information in and of itself, regardless of the condition being detected. Further, participants were informed that the current standard of care is the integrated screen and that doctors are thus likely to suggest this option to patients as a firsttier test. Indeed, the recommendation of a health-care provider was listed higher than personal or family beliefs in testing decision-making factors. The recommendation of a health-care provider may therefore be a significant contributor to the decision to undergo integrated screening rather than cffDNA testing. Similarly, those who said they would refuse testing may regard the information as unnecessary, regardless of the condition. Significant difference was shown in the consideration of termination between trisomy 13/18 and trisomy 21. A higher percentage of respondents indicated that they would be more likely to consider terminating a pregnancy affected by trisomy 13/18 than a pregnancy affected by trisomy 21, which most likely indicates consideration of the increased severity of trisomy 13/18. However, the reported willingness to consider termination seen here is considerably lower than the actual statistics for termination post trisomy 21 diagnosis, which range from 67 to 85% in the United States. 40 The high reported willingness to consider termination for trisomy 21 is also at odds with previous studies of individuals and families with trisomy 21, which report high levels of satisfaction and quality of life, although there is some selection bias in these findings. 41, 42 Patient advocates have long suggested that this dichotomy reflects a lack of education and nuanced understanding of the reality of living with genetic conditions, which can be overcome with better educational approaches to prenatal counseling. 43 Limitations Finally, as noted in the results section, there are statistically significant differences between the study sample and the national census on several demographic factors. In particular, as reported elsewhere, educational achievement and income may affect the reported willingness to undergo testing. By the same token the underrepresentation of certain minority populations may give the impression of greater enthusiasm for testing among the population as a whole; past studies have shown that minority populations have lower uptake rates of prenatal testing than Caucasian populations. 44 On the other hand, these demographics may be a more accurate portrayal of those populations that are most likely to be offered non-invasive prenatal testing methods. Given the high price points and uncertain insurance coverage, it is likely that this testing will be accessed, at least initially, by more socio-economically advantaged populations.
Another limitation concerns the fact that participants received relatively little information on the complex nature of risk calculations and phenotypic expression of trisomies. This is counter to the recommendation of many disability advocates, who frequently campaign for more nuanced information in the genetic counseling process. 45, 46 However, it may not be dissimilar to actual clinical testing presentations, especially in resourcelimited settings. 47 A third limitation is suggested by the disparity between anticipated invasive testing and termination rates and the experience of clinical practitioners. This disparity suggests that individuals cannot always accurately predict their future actions, which may restrict the generalizability of the data gathered here. There is a well-known expectation bias among participants in social science research, particularly that which deals with morally controversial subjects. Especially among populations with strong cultural or religious stigma surrounding abortion, individuals are less likely to publically confess a willingness to undergo pregnancy termination. The way in which these attitudes change when confronted with the reality of a positive diagnosis may account in part for the discrepancy in reported vs actual terminations.
CONCLUSION
Overall, these results suggest moderate support for the use of cffDNA testing in high-risk pregnancies for the detection of trisomy. Despite differences in mortality and morbidity between trisomy 13 and 18 and trisomy 21, there were no statistical differences between uptake of testing for the two sets of conditions, with the exception of a slight increase in those who indicated that they would prefer to have both screening and cffDNA testing for trisomy 13 and 18. There was also greater support for consideration of termination when considering a positive result for trisomy 13 and 18 as opposed to trisomy 21. Although these numbers seem to suggest a measured consideration of the probable quality-of-life impact of these respective conditions, reported willingness to consider termination remained significantly lower than the rates of actual termination reported clinically.
Although the potential to test for aneuploidy earlier in the pregnancy does offer benefits in terms of the possibility of earlier reassurance or decisions surrounding termination when medical, rather than surgical, abortions are still possible, it also condenses the informed consent process and may discourage health-care providers and patients from having comprehensive conversations about the realities of living with a genetic condition. 32, 37 It is of some concern to note that respondents consistently valued the recommendation of a physician when making prenatal testing decisions despite the fact that most obstetric clinicians do not have training in genetics and may be unprepared to have knowledgeable conversations about the implications of expanded prenatal genetic testing.
In addition, a small but significant portion of the sample indicated that they would continue to support the refusal of any form of prenatal testing, even when offered a non-invasive testing option and despite differences in the severity of the condition being tested. This is contrary to a previous prediction that suggested that the limiting factor for many women who decline testing is the risk of miscarriage. 26 We suggest that stakeholders should direct proactive attention to reforming and strengthening the informed consent process in order to effect the most ethical implementation of cffDNA testing.
